219 related articles for article (PubMed ID: 23588304)
1. Replication of TPMT and ABCC3 genetic variants highly associated with cisplatin-induced hearing loss in children.
Pussegoda K; Ross CJ; Visscher H; Yazdanpanah M; Brooks B; Rassekh SR; Zada YF; Dubé MP; Carleton BC; Hayden MR;
Clin Pharmacol Ther; 2013 Aug; 94(2):243-51. PubMed ID: 23588304
[TBL] [Abstract][Full Text] [Related]
2. The role of inherited TPMT and COMT genetic variation in cisplatin-induced ototoxicity in children with cancer.
Yang JJ; Lim JY; Huang J; Bass J; Wu J; Wang C; Fang J; Stewart E; Harstead EH; E S; Robinson GW; Evans WE; Pappo A; Zuo J; Relling MV; Onar-Thomas A; Gajjar A; Stewart CF
Clin Pharmacol Ther; 2013 Aug; 94(2):252-9. PubMed ID: 23820299
[TBL] [Abstract][Full Text] [Related]
3. [The analysis of the association of the polymorphic variants of the TPMT, COMT, and ABCC3 genes with the development of hearing disorders induced by the cisplatin treatment].
Mironovich OL; Bliznetz EA; Garbaruk ES; Belogurova MB; Subora NV; Varfolomeeva SR; Kachanov DY; Shamanskaya TV; Markova TG; Polyakov AV
Vestn Otorinolaringol; 2018; 83(4):60-66. PubMed ID: 30113582
[TBL] [Abstract][Full Text] [Related]
4. Genetics of cisplatin ototoxicity: confirming the unexplained?
Boddy AV
Clin Pharmacol Ther; 2013 Aug; 94(2):198-200. PubMed ID: 23872836
[TBL] [Abstract][Full Text] [Related]
5. Challenges in interpreting the evidence for genetic predictors of ototoxicity.
Ratain MJ; Cox NJ; Henderson TO
Clin Pharmacol Ther; 2013 Dec; 94(6):631-5. PubMed ID: 24241639
[TBL] [Abstract][Full Text] [Related]
6. TPMT, COMT and ACYP2 genetic variants in paediatric cancer patients with cisplatin-induced ototoxicity.
Thiesen S; Yin P; Jorgensen AL; Zhang JE; Manzo V; McEvoy L; Barton C; Picton S; Bailey S; Brock P; Vyas H; Walker D; Makin G; Bandi S; Pizer B; Hawcutt DB; Pirmohamed M
Pharmacogenet Genomics; 2017 Jun; 27(6):213-222. PubMed ID: 28445188
[TBL] [Abstract][Full Text] [Related]
7. Genetic variants in TPMT and COMT are associated with hearing loss in children receiving cisplatin chemotherapy.
Ross CJ; Katzov-Eckert H; Dubé MP; Brooks B; Rassekh SR; Barhdadi A; Feroz-Zada Y; Visscher H; Brown AM; Rieder MJ; Rogers PC; Phillips MS; Carleton BC; Hayden MR;
Nat Genet; 2009 Dec; 41(12):1345-9. PubMed ID: 19898482
[TBL] [Abstract][Full Text] [Related]
8. Clinical and genetic associations for carboplatin-related ototoxicity in children treated for retinoblastoma: A retrospective noncomparative single-institute experience.
Soliman SE; D'Silva CN; Dimaras H; Dzneladze I; Chan H; Gallie BL
Pediatr Blood Cancer; 2018 May; 65(5):e26931. PubMed ID: 29350448
[TBL] [Abstract][Full Text] [Related]
9. Genetic markers of cisplatin-induced hearing loss in children.
Carleton BC; Ross CJ; Pussegoda K; Bhavsar AP; Visscher H; Lee JW; Brooks B; Rassekh SR; Dubé MP; Hayden MR
Clin Pharmacol Ther; 2014 Sep; 96(3):296-8. PubMed ID: 25141953
[TBL] [Abstract][Full Text] [Related]
10. Role of TPMT and COMT genetic variation in cisplatin-induced ototoxicity.
Carleton BC; Ross CJ; Bhavsar AP; Amstutz U; Pussegoda K; Visscher H; Lee JW; Brooks B; Rassekh SR; Dubé MP; Hayden MR
Clin Pharmacol Ther; 2014 Mar; 95(3):253. PubMed ID: 24193170
[No Abstract] [Full Text] [Related]
11. Influence of genetic variants in TPMT and COMT associated with cisplatin induced hearing loss in patients with cancer: two new cohorts and a meta-analysis reveal significant heterogeneity between cohorts.
Hagleitner MM; Coenen MJ; Patino-Garcia A; de Bont ES; Gonzalez-Neira A; Vos HI; van Leeuwen FN; Gelderblom H; Hoogerbrugge PM; Guchelaar HJ; Te Loo MW
PLoS One; 2014; 9(12):e115869. PubMed ID: 25551397
[TBL] [Abstract][Full Text] [Related]
12. Response to "evaluation of pharmacogenetic markers to predict the risk of Cisplatin-induced ototoxicity".
Carleton BC; Ross CJ; Bhavsar AP; Lee JW; Visscher H; Rassekh SR; Hayden MR
Clin Pharmacol Ther; 2014 Aug; 96(2):158. PubMed ID: 24755913
[No Abstract] [Full Text] [Related]
13. Evaluation of pharmacogenetic markers to predict the risk of Cisplatin-induced ototoxicity.
Lanvers-Kaminsky C; Malath I; Deuster D; Ciarimboli G; Boos J; Am Zehnhoff-Dinnesen AG
Clin Pharmacol Ther; 2014 Aug; 96(2):156-7. PubMed ID: 24642735
[No Abstract] [Full Text] [Related]
14. Role of Cisplatin Dose Intensity and TPMT Variation in the Development of Hearing Loss in Children.
Siemens A; Brooks B; Rassekh SR; Meijer AJM; van den Heuvel-Eibrink MM; Xu W; Loucks CM; Ross CJD; Carleton BC;
Ther Drug Monit; 2023 Jun; 45(3):345-353. PubMed ID: 36917731
[TBL] [Abstract][Full Text] [Related]
15. Usefulness of current candidate genetic markers to identify childhood cancer patients at risk for platinum-induced ototoxicity: Results of the European PanCareLIFE cohort study.
Langer T; Clemens E; Broer L; Maier L; Uitterlinden AG; de Vries ACH; van Grotel M; Pluijm SFM; Binder H; Mayer B; von dem Knesebeck A; Byrne J; van Dulmen-den Broeder E; Crocco M; Grabow D; Kaatsch P; Kaiser M; Spix C; Kenborg L; Winther JF; Rechnitzer C; Hasle H; Kepak T; van der Kooi AF; Kremer LC; Kruseova J; Bielack S; Sorg B; Hecker-Nolting S; Kuehni CE; Ansari M; Kompis M; van der Pal H; Parfitt R; Deuster D; Matulat P; Tillmanns A; Tissing WJE; Beck JD; Elsner S; Am Zehnhoff-Dinnesen A; van den Heuvel-Eibrink MM; Zolk O;
Eur J Cancer; 2020 Oct; 138():212-224. PubMed ID: 32905960
[TBL] [Abstract][Full Text] [Related]
16. Pharmacogenomics of cisplatin-induced ototoxicity.
Mukherjea D; Rybak LP
Pharmacogenomics; 2011 Jul; 12(7):1039-50. PubMed ID: 21787192
[TBL] [Abstract][Full Text] [Related]
17. Effects of sodium thiosulfate versus observation on development of cisplatin-induced hearing loss in children with cancer (ACCL0431): a multicentre, randomised, controlled, open-label, phase 3 trial.
Freyer DR; Chen L; Krailo MD; Knight K; Villaluna D; Bliss B; Pollock BH; Ramdas J; Lange B; Van Hoff D; VanSoelen ML; Wiernikowski J; Neuwelt EA; Sung L
Lancet Oncol; 2017 Jan; 18(1):63-74. PubMed ID: 27914822
[TBL] [Abstract][Full Text] [Related]
18. Cisplatin-induced hearing loss: the need for a long-term evaluating system.
Yasui N; Adachi N; Kato M; Koh K; Asanuma S; Sakata H; Hanada R
J Pediatr Hematol Oncol; 2014 May; 36(4):e241-5. PubMed ID: 24072246
[TBL] [Abstract][Full Text] [Related]
19. Platinum-induced hearing loss after treatment for childhood cancer.
van As JW; van den Berg H; van Dalen EC
Cochrane Database Syst Rev; 2016 Aug; 2016(8):CD010181. PubMed ID: 27486906
[TBL] [Abstract][Full Text] [Related]
20. Hearing loss in Mexican children treated with cisplatin.
Castelán-Martínez OD; Jiménez-Méndez R; Rodríguez-Islas F; Fierro-Evans M; Vázquez-Gómez BE; Medina-Sansón A; Clark P; Carleton B; Ross C; Hildebrand C; Castañeda-Hernández G; Rivas-Ruiz R
Int J Pediatr Otorhinolaryngol; 2014 Sep; 78(9):1456-60. PubMed ID: 25037447
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
